Search clinical trials for: Triweekly Cetuximab

Total 1027 results

Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
Shanghai Changzheng Hospital

Unknown

EGFR Monoclonal Antibody for Advanced Gastric Cancer

Gastric Cancer | Cetuximab | Nimotuzumab

China
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Biomarker Directed Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Austria
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation

Completed

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States
Per Pfeiffer

Completed

Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis

Folliculitis

Denmark
Wayne State University

Completed

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)

Heroin Dependence | Opioid Use Disorder

United States
Federation Francophone de Cancerologie Digestive

Completed

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

Colorectal Cancer

France
Per Pfeiffer
Odense University Hospital

Withdrawn

Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer (CECAVI)

Head and Neck Neoplasms

Denmark
Per Pfeiffer
Merck Serono International SA

Completed

Nordic 8 - A Phase II Trial

Metastatic Colorectal Cancer

Denmark, Norway, Sweden
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

Switzerland, France, Austria, Germany, Hungary
Louisiana State University Health Sciences Center...

Terminated

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Cancer

United States
Teva Pharmaceuticals USA

Withdrawn

An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.

Evaluation of QTc Interval
Dorte Nielsen

Completed

Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

Cholangiocarcinoma

Denmark
Washington University School of Medicine
Celgene

Completed

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

Head and Neck Neoplasms

United States
Washington University School of Medicine
Celgene Corporation

Completed

Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Lund University Hospital

Completed

A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. (ARTSCANIII)

Locally Advanced Head and Neck Cancer

Sweden
Fudan University

Unknown

Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases
University of Texas Southwestern Medical Center

Completed

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
University of Texas Southwestern Medical Center

Completed

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
UNC Lineberger Comprehensive Cancer Center

Completed

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
ImmunityBio, Inc.

Unknown

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Squamous Cell Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer

Colorectal Cancer
Eli Lilly and Company

Completed

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

Colorectal Cancer | Colorectal Carcinoma | Colorectal Tumor

United States
M.D. Anderson Cancer Center

Completed

Bevacizumab in Multiple Phase I Combinations

Advanced Cancer

United States
Chinese University of Hong Kong

Completed

Cetuximab Rechallenge Study

Metastatic Colorectal Cancer

Hong Kong
Medical University Innsbruck

Terminated

Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck

Head and Neck Neoplasms

Austria
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group

Completed

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

Stage III Colon Cancer | Adenocarcinoma of the Colon

United States, Canada, Puerto Rico
University of Chicago
Novartis Pharmaceuticals

Terminated

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb; National Cancer Institute (NCI); Southwest Oncology Group; Aptu...

Completed

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada
Shanghai Jiao Tong University School of Medicine
Fudan University; Tongji University; Second Military Medical University

Completed

Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer

Oral Cancer | Locally Advanced Malignant Neoplasm | Oropharyngeal Carcinoma

China
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
Arbeitsgemeinschaft medikamentoese Tumortherapie
Medical University of Graz

Terminated

Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (AGMT_HNO_PN)

Locally Advanced Malignant Neoplasm | Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Oral Cavity Stage III | Squamous Cell Carcinoma of the Oral Cavity Stage IV | Laryngeal Squamous Cell Carcinoma Stage... and other conditions

Austria
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (2007-01)

HNSCC

France
Abramson Cancer Center of the University of Pennsylvania
Bristol-Myers Squibb; Roche Pharma AG

Terminated

Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma

Rectal Cancer
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer

United States
NYU Langone Health
Bristol-Myers Squibb; Eli Lilly and Company

Completed

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

Neoplasm Metastasis | Colorectal Cancer

United States
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Breast Cancer | Neoplasm Metastasis | Colorectal Neoplasms

United States
Sun Yat-sen University

Completed

FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (FOCULM)

Metastatic Colorectal Cancer

China
Armando Orlandi

Completed

Erbitux MEtastatic Colorectal Cancer Strategy Study

Antineoplastic Agents

Italy
Eben Rosenthal
National Cancer Institute (NCI)

Terminated

Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery

Malignant Glioma | Brain Neoplasm

United States
Institut Cancerologie de l'Ouest

Terminated

Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer (SKINUX)

Colorectal Cancer Metastatic | Skin Toxicity

France
M.D. Anderson Cancer Center
Eli Lilly and Company

Completed

Preoperative Treatment With Cetuximab and/or IMC-A12

Head and Neck Squamous Cell Carcinoma

United States
SFJ Pharmaceuticals X, LTD.
Merck KGaA, Darmstadt, Germany; AIO-Studien-gGmbH; Academic and Community Cancer... and other collaborators

Withdrawn

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (AMELION)

Metastatic Colorectal Cancer
Sichuan Cancer Hospital and Research Institute
Southwest Hospital, China; Affiliated Cancer Hospital & Institute of Guangzhou... and other collaborators

Unknown

Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma

China
National Cancer Institute (NCI)

Completed

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (ADCC)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell... and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract

Head and Neck Cancer | Precancerous Condition

United States, Canada
University Hospital Schleswig-Holstein

Completed

Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer

Esophageal Cancer

Germany
Lund University Hospital
Merck Sharp & Dohme LLC

Completed

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (NOAC8)

Locally Advanced Cancer in the Anal Region

Sweden, Norway
Millennium Pharmaceuticals, Inc.

Completed

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States, Spain, France, United Kingdom

Search clinical trials for: Triweekly Cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations